Abstract:Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a systemic disorder associated with polycystic liver disease (PLD) and other extrarenal manifestations, the most common monogenic cause of end-stage kidney disease, and a major burden for public health. Many studies have shown that alterations in G-protein and cAMP signaling play a central role in its pathogenesis. As for many other diseases (35% of all approved drugs target G-protein coupled receptors (GPCRs) or proteins functioning upstream or downstream from GPCRs), treatments targeting GPCR have shown effectiveness in slowing the rate of progression of ADPKD. Tolvaptan, a vasopressin V2 receptor antagonist is the first drug approved by regulatory agencies to treat rapidly progressive ADPKD. Long-acting somatostatin analogs have also been effective in slowing the rates of growth of polycystic kidneys and liver. Although no treatment has so far been able to prevent the development or stop the progression of the disease, these encouraging advances point to G-protein and cAMP signaling as a promising avenue of investigation that may lead to more effective and safe treatments. This will require a better understanding of the relevant GPCRs, G-proteins, cAMP effectors, and of the enzymes and A-kinase anchoring proteins controlling the compartmentalization of cAMP signaling. The purpose of this review is to provide an overview of general GPCR signaling; the function of polycystin-1 (PC1) as a putative atypical adhesion GPCR (aGPCR); the roles of PC1, polycystin-2 (PC2) and the PC1-PC2 complex in the regulation of calcium and cAMP signaling; the cross-talk of calcium and cAMP signaling in PKD; and GPCRs, adenylyl cyclases, cyclic nucleotide phosphodiesterases, and protein kinase A as therapeutic targets in ADPKD.

Polycystic Kidney Disease: Novel Insights into Polycystin Function.

The Advances of Polycystin-1

Autosomal Dominant Polycystic Kidney Disease with Ectopic Unilateral Multicystic Dysplastic Kidney

The Function of Polycystin-1 and Polycystin-2 in Cardiovascular System

Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling

Protein Phosphatase 1α Interacts with a Novel Ciliary Targeting Sequence of Polycystin‐1 and Regulates Polycystin‐1 Trafficking

ADPKD-Causing Missense Variants in Polycystin-1 Disrupt Cell Surface Localization or Polycystin Channel Function

Polycystin-2 Mediated Calcium Signalling in the Dictyostelium Model for Autosomal Dominant Polycystic Kidney Disease

Cross-Species Insights into Autosomal Dominant Polycystic Kidney Disease: Provide an Alternative View on Research Advancement.

Advances in autosomal dominant polycystic kidney disease

Cilia to basement membrane signalling is a biomechanical driver of autosomal dominant polycystic kidney disease

The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Disease-A Primer for Clinicians

Polycystin-1, the product of the polycystic kidney disease gene PKD1, is post-translationally modified by palmitoylation

Insights into Autosomal Dominant Polycystic Kidney Disease from Genetic Studies

Ion channel function of polycystin-2/polycystin-1 heteromer revealed by structure-guided mutagenesis

Provide an Alternative View on Research Advancement

Polycystin-1 dependent regulation of polycystin-2 via GRP94, a member of HSP90 family that resides in the endoplasmic reticulum

Single-Cell and CellChat Resolution Identifies Collecting Duct Cell Subsets and Their Communications with Adjacent Cells in PKD Kidneys

Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways

Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease

Inhibiting centrosome clustering reduces cystogenesis and improves kidney function in autosomal dominant polycystic kidney disease